Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
650.18B
Market cap650.18B
Price-Earnings ratio
31.29
Price-Earnings ratio31.29
Dividend yield
1.96%
Dividend yield1.96%
Average volume
6.61M
Average volume6.61M
High today
$273.73
High today$273.73
Low today
$268.59
Low today$268.59
Open price
$271.74
Open price$271.74
Volume
2.26M
Volume2.26M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$173.33
52 Week low$173.33

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $269.80, with a market capitalization of 650.18B. The stock trades at a price-to-earnings (P/E) ratio of 31.29 and offers a dividend yield of 1.96%.

During the trading session on 2026-09-21, Johnson & Johnson(JNJ) shares reached a daily high of $273.73 and a low of $268.59. At a current price of $269.80, the stock is +0.4% higher than the low and still -1.4% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 2.26M, versus its average volume of 6.61M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $173.33.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $173.33.

JNJ News

New York Times 3h
Bears’ Caleb Williams week-to-week with hamstring injury, Ben Johnson says - The New York Times

...

Bears’ Caleb Williams week-to-week with hamstring injury, Ben Johnson says - The New York Times
Nasdaq 4h
The Investing Playbook for Retirees Who Can't Afford to Lose

The Investing Playbook for Retirees Who Can't Afford to Lose Key Points Remaining diversified is one of the best ways to reduce risk. A cash fund can prevent y...

The Investing Playbook for Retirees Who Can't Afford to Lose
TipRanks 6h
J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

Johnson & Johnson announced topline results from the Phase 3 study evaluating Caplyta for the treatment of manic episodes with or without mixed features in adul...

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
22.2%
Sell
7.4%

More JNJ News

TipRanks 7h
Johnson & Johnson announces ‘positive’ results from Phase 3 trial of Caplyta

Johnson & Johnson announced positive topline results from the pivotal Phase 3 study evaluating Caplyta for the treatment of manic episodes with or without mixed...

Simply Wall St 3d
Johnson & Johnson Advances Sjögren's Therapies With New Biomarker Trial Data

Johnson & Johnson (NYSE: JNJ) reported new biomarker findings tied to its targeted therapies for Sjögren's syndrome in ongoing trials. The pharmaceutical segme...

Johnson & Johnson Advances Sjögren's Therapies With New Biomarker Trial Data
Nasdaq 4d
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

Key Points Johnson & Johnson has raised its dividend for 64 straight years, but faces billions in talc-related litigation liabilities. Kenvue offers a higher...

Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
24/7 Wall St. 5d
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees

Investing Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees Realty Income pays you every month while Johnson and Johnson barely clears...

Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees
Nasdaq 5d
My Top 5 Favorite Stocks for an Uncertain Market

Key Points These companies offer essential products or medicines, or have qualities that favor resilience during tough times. And you may benefit from these s...

My Top 5 Favorite Stocks for an Uncertain Market
Nasdaq 6d
Dow Analyst Moves: JNJ

The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Johnson & Johnso...

Dow Analyst Moves: JNJ
Benzinga 6d
Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival

Johnson & Johnson (NYSE:JNJ) on Monday announced new clinical results from its Phase 2b COPERNICUS study evaluating subcutaneous RYBREVANT FASPRO combined with...

Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.